MX2021002500A - Anticuerpos y secuencias de nucleotidos novedosos, y sus usos. - Google Patents
Anticuerpos y secuencias de nucleotidos novedosos, y sus usos.Info
- Publication number
- MX2021002500A MX2021002500A MX2021002500A MX2021002500A MX2021002500A MX 2021002500 A MX2021002500 A MX 2021002500A MX 2021002500 A MX2021002500 A MX 2021002500A MX 2021002500 A MX2021002500 A MX 2021002500A MX 2021002500 A MX2021002500 A MX 2021002500A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody molecules
- nucleotide sequences
- novel antibodies
- ctla
- viruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192311.1A EP3617230A1 (en) | 2018-09-03 | 2018-09-03 | Novel antibodies and nucleotide sequences, and uses thereof |
| PCT/EP2019/073488 WO2020049001A1 (en) | 2018-09-03 | 2019-09-03 | Novel antibodies and nucleotide sequences, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002500A true MX2021002500A (es) | 2021-08-11 |
Family
ID=63490358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002500A MX2021002500A (es) | 2018-09-03 | 2019-09-03 | Anticuerpos y secuencias de nucleotidos novedosos, y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12291569B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3617230A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7515461B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102866553B1 (cg-RX-API-DMAC10.html) |
| CN (2) | CN119161482A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019333862B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112021003916A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3111153A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL281198A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2021002500A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020049001A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3552615T3 (da) | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| TW202321458A (zh) * | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| RU2489486C2 (ru) | 2006-06-20 | 2013-08-10 | Трансжене С.А. | Процесс получения поксвирусов и композиции поксвирусов |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| AU2008250596C1 (en) | 2007-05-14 | 2010-11-25 | Bavarian Nordic A/S | Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| DK2212345T3 (en) | 2007-11-19 | 2016-03-21 | Transgene Sa | Oncolytic poxvirus vectors |
| AU2009214768B2 (en) | 2008-02-12 | 2015-01-22 | Sanofi Pasteur Limited | Methods using ion exchange and gel filtration chromatography for poxvirus purification |
| SG176554A1 (en) | 2009-05-12 | 2012-01-30 | Transgene Sa | Method for orthopoxvirus production and purification |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| KR102022952B1 (ko) | 2011-08-05 | 2019-09-20 | 신라젠(주) | 백시니아 바이러스의 생산을 위한 방법 및 조성물 |
| EP2912063A1 (en) | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| DK3552615T3 (da) * | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| US10196445B1 (en) * | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| AU2016370648B2 (en) * | 2015-12-15 | 2023-03-09 | OncoC4, Inc. | Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof |
| US20190241658A1 (en) * | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| NL2017270B1 (en) * | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| IL270743B2 (en) * | 2017-05-19 | 2024-09-01 | Wuxi Biologics Shanghai Co Ltd | Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof |
-
2018
- 2018-09-03 EP EP18192311.1A patent/EP3617230A1/en not_active Withdrawn
-
2019
- 2019-09-03 CN CN202411416221.7A patent/CN119161482A/zh active Pending
- 2019-09-03 US US17/272,740 patent/US12291569B2/en active Active
- 2019-09-03 CN CN201980055914.9A patent/CN112912398B/zh active Active
- 2019-09-03 CA CA3111153A patent/CA3111153A1/en active Pending
- 2019-09-03 WO PCT/EP2019/073488 patent/WO2020049001A1/en not_active Ceased
- 2019-09-03 JP JP2021512914A patent/JP7515461B2/ja active Active
- 2019-09-03 AU AU2019333862A patent/AU2019333862B2/en active Active
- 2019-09-03 MX MX2021002500A patent/MX2021002500A/es unknown
- 2019-09-03 BR BR112021003916-3A patent/BR112021003916A2/pt unknown
- 2019-09-03 KR KR1020217009505A patent/KR102866553B1/ko active Active
- 2019-09-03 EP EP19761869.7A patent/EP3847193A1/en active Pending
-
2021
- 2021-03-02 IL IL281198A patent/IL281198A/en unknown
-
2024
- 2024-04-02 JP JP2024059450A patent/JP7681151B2/ja active Active
-
2025
- 2025-04-02 US US19/098,185 patent/US20250257135A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019333862B2 (en) | 2025-10-16 |
| JP7681151B2 (ja) | 2025-05-21 |
| EP3847193A1 (en) | 2021-07-14 |
| US12291569B2 (en) | 2025-05-06 |
| JP7515461B2 (ja) | 2024-07-12 |
| CN112912398A (zh) | 2021-06-04 |
| AU2019333862A1 (en) | 2021-03-11 |
| JP2022512544A (ja) | 2022-02-07 |
| IL281198A (en) | 2021-04-29 |
| KR20210055722A (ko) | 2021-05-17 |
| JP2024091656A (ja) | 2024-07-05 |
| CN119161482A (zh) | 2024-12-20 |
| US20220041723A1 (en) | 2022-02-10 |
| BR112021003916A2 (pt) | 2021-05-25 |
| EP3617230A1 (en) | 2020-03-04 |
| WO2020049001A1 (en) | 2020-03-12 |
| CA3111153A1 (en) | 2020-03-12 |
| CN112912398B (zh) | 2024-10-25 |
| KR102866553B1 (ko) | 2025-10-01 |
| US20250257135A1 (en) | 2025-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| ECSP17027870A (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer | |
| CL2017000515A1 (es) | Cd123 agentes enlazadores y su uso | |
| MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
| CL2017001920A1 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
| MX2023013729A (es) | Receptores quimericos de flt3 y metodos de uso de los mismos. | |
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| BR112018067696A2 (pt) | membros de ligação à pd-l1 | |
| CO2017004516A2 (es) | Anticuerpos anti-ox40 humanizados | |
| PH12017501166B1 (en) | Antibodies to tigit | |
| EA201790413A1 (ru) | Антитела против tigit | |
| EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
| MX392779B (es) | Anticuerpos anti-cd27 | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| PE20151893A1 (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular | |
| IL280145A (en) | Methods and compositions using recombinant dendritic cells for cancer therapy | |
| UY37630A (es) | Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer | |
| EA201992586A1 (ru) | Способы лечения с помощью полипептидов внеклеточного домена cd80 | |
| MX2019015194A (es) | Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas. | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
| MX2019011124A (es) | Anticuerpo anti-ceacam1 y uso del mismo. | |
| AR097570A1 (es) | Composiciones y métodos para incrementar la migración de células mesenquimales del estroma hacia tumores | |
| EA201992875A1 (ru) | T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения |